Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457738 | 0.87 | KDM4E (0.42) | CYP1A2LMNATP53MAPTGLA | |
| SCHEMBL3456163 | 0.84 | LMNA (0.37) | L3MBTL1PLA2G2AGRM2LMNATP53 | |
| SCHEMBL3457404 | 0.82 | PLA2G2A (0.46) | PLA2G2ALMNATP53MAPT | |
| SCHEMBL3456970 | 0.81 | CXCR2 (0.41) | L3MBTL1LMNATP53MAPTPDE10A | |
| SCHEMBL3457700 | 0.80 | APP (0.46) | L3MBTL1PLA2G2ALMNATP53MAPT | |
| SCHEMBL3456550 | 0.77 | PLA2G2A (0.39) | L3MBTL1NTRK1PLA2G2AGRM2MAPT | |
| SCHEMBL14352265 | 0.76 | MAOA (0.42) | HTR2ALMNATP53MAPTGLA | |
| SCHEMBL29219438 | 0.76 | KCNH2 (0.48) | PLA2G2APDE10A | |
| SCHEMBL14128989 | 0.73 | KDM4E (0.60) | LMNAMAPTNPSR1 | |
| SCHEMBL6089983 | 0.71 | KMT2A (0.48) | L3MBTL1CYP1A2LMNAMAPTGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258688-B1 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| EP-2258688-A1 | Pyridinone derivatives for treatment of atherosclerosis | SmithKline Beecham Limited (GB) | 2010-12-08 | — | — | EP | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235566-B2 | Pyridinone derivatives for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014793-A1 | Pyridinone derivatives for treatment of atherosclerosis | PNPO, PLA2G7, PLA2G4B | L3MBTL1 4276/4885CYP1A1 761/4885CYP1A2 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.